Shopping Cart 0
Cart Subtotal
USD 0

Athenex Inc (ATNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company's orascovery products candidates include oral formulations of paclitaxel (Oraxol), irinotecan (Oratecan), and docetaxel (Oradoxel) for the treatment of metastatic breast, colorectal, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancers. Its Src kinase product candidates comprises KX-01, a novel orally administered small molecule compound for the treatment of actinic keratosis; and KX-02 for solid tumors. Athenex offers services including drug discovery, drug formulation and clinical development, API manufacturing services. The company partners with pharmaceutical companies, universities and research institutions for the advancement and commercialization of its products. It has operations with product manufacturing facilities in the US, China, Taiwan and Hong Kong. Athenex is headquartered in Buffalo, New York, the US.

Athenex Inc (ATNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11

Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Athenex Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 14

Venture Financing 15

Athenex Raises USD20 Million in Venture Debt Financing 15

Athenex Raises USD38 Million in Financing 16

Kinex Pharma Raises USD10 Million in Venture Financing 17

Kinex Pharma Raises USD74.4 Million in Venture Financing 18

Kinex Pharma Raises USD 0.3 Million In Venture Financing 19

Kinex Pharma Raises Funds In First Tranche Of Financing Round 20

Kinex Pharma Raises USD 5 Million In Venture Financing 21

Private Equity 22

Athenex to Raise USD50 Million in Equity Financing 22

Partnerships 23

Athenex to Form Joint Venture with Xiangxue Life Sciences 23

Athenex Forms Joint Venture with SunGen Pharma 24

Athenex Enters into Agreement with Imuna Pharm 25

Athenex Enters into Partnership with Eli Lilly and Company 26

Athenex Enters into Agreement with Fort Schuyler Management 27

Licensing Agreements 28

Athenex Enters into Licensing Agreement with Avalon PolyTom 28

Almirall to Enter into Licensing Agreement with Athenex for KX2-391 30

Athenex to Enter into Licensing Agreement with Gland Pharma 31

Athenex to Enter into Licensing Agreement with Gland Pharma 32

Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 33

PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 34

Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 35

Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 37

Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 39

Equity Offering 41

Athenex Completes Partial Exercise of Over-Allotment Option of Public Offering of Shares for USD72.7 Million 41

Athenex Raises USD76 Million in IPO 43

Athenex Raises USD3.5 Million in Private Placement of Shares 45

Athenex Raises USD5 Million in Private Placement of Shares 46

Athenex Raises USD6.6 Million in Private Placement of Shares 47

Kinex Pharma Raises Funds through Private Placement of Shares 48

Athenex Raises USD4 Million in Private Placement of Shares 49

Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 50

Kinex Pharma Completes Private Placement Of Shares For USD 40 Million 51

Acquisition 52

Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 52

Athenex Acquires Polymed Therapeutics 53

Kinex Pharma Acquires QuaDPharma for USD5.5 Million 54

Athenex Inc-Key Competitors 55

Athenex Inc-Key Employees 56

Athenex Inc-Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Joint Venture 59

Recent Developments 60

Financial Announcements 60

Aug 14, 2018: Athenex reports second quarter 2018 financial results 60

May 14, 2018: Athenex Announces First Quarter 2018 Results 63

Mar 26, 2018: Athenex Announces Fourth Quarter and Full-Year 2017 Results 65

Nov 09, 2017: Athenex Announces Third Quarter 2017 Results 67

Aug 14, 2017: Athenex Announces Second Quarter 2017 Results 70

Corporate Communications 73

Aug 20, 2018: Athenex names Randoll Sze as Chief Financial Officer 73

Jul 09, 2018: Athenex Appoints Timothy Cook As Senior Vice President Of Global Commercial Oncology 74

Jun 15, 2018: Athenex Appoints Benson Tsang As Board Director 75

Apr 30, 2018: Athenex Announces Transition of James Zukin from Board of Directors to Advisory Role 76

Dec 01, 2017: Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle 77

Mar 01, 2017: Athenex announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer 78

Feb 27, 2017: Athenex appoints veteran J. Nick Riehle as Chief Financial Officer 79

Government and Public Interest 80

Sep 11, 2017: Athenex Announces Grant Disbursement Agreement with New York State for Dunkirk Facility 80

Product News 81

Oct 15, 2018: Athenex and Xiangxue Life Sciences announce preliminary results of patients receiving T-Cell receptor affinity enhancing specific T-Cell therapy (TAEST) showed encouraging positive clinical signals 81

Aug 10, 2017: Athenex Pharma Solutions, an Athenex, Company, Launches Three New Sterile Injectable Products from its 503(B) Facility 82

Aug 01, 2017: Athenex Announces Recent Product Launches in Commercial Business 83

Clinical Trials 84

Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting 84

Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis 85

Other Significant Developments 86

Jul 18, 2018: PolyU-axis therapeutics joint center for immunotherapy launched to develop innovative cancer treatments 86

Jul 02, 2018: Athenex forms new alliances in Asia to expand oncology pipeline 87

Feb 13, 2018: Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units 88

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Athenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Athenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Athenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Athenex Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11

Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 14

Athenex Raises USD20 Million in Venture Debt Financing 15

Athenex Raises USD38 Million in Financing 16

Kinex Pharma Raises USD10 Million in Venture Financing 17

Kinex Pharma Raises USD74.4 Million in Venture Financing 18

Kinex Pharma Raises USD 0.3 Million In Venture Financing 19

Kinex Pharma Raises Funds In First Tranche Of Financing Round 20

Kinex Pharma Raises USD 5 Million In Venture Financing 21

Athenex to Raise USD50 Million in Equity Financing 22

Athenex to Form Joint Venture with Xiangxue Life Sciences 23

Athenex Forms Joint Venture with SunGen Pharma 24

Athenex Enters into Agreement with Imuna Pharm 25

Athenex Enters into Partnership with Eli Lilly and Company 26

Athenex Enters into Agreement with Fort Schuyler Management 27

Athenex Enters into Licensing Agreement with Avalon PolyTom 28

Almirall to Enter into Licensing Agreement with Athenex for KX2-391 30

Athenex to Enter into Licensing Agreement with Gland Pharma 31

Athenex to Enter into Licensing Agreement with Gland Pharma 32

Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 33

PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 34

Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 35

Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 37

Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 39

Athenex Completes Partial Exercise of Over-Allotment Option of Public Offering of Shares for USD72.7 Million 41

Athenex Raises USD76 Million in IPO 43

Athenex Raises USD3.5 Million in Private Placement of Shares 45

Athenex Raises USD5 Million in Private Placement of Shares 46

Athenex Raises USD6.6 Million in Private Placement of Shares 47

Kinex Pharma Raises Funds through Private Placement of Shares 48

Athenex Raises USD4 Million in Private Placement of Shares 49

Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 50

Kinex Pharma Completes Private Placement Of Shares For USD 40 Million 51

Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 52

Athenex Acquires Polymed Therapeutics 53

Kinex Pharma Acquires QuaDPharma for USD5.5 Million 54

Athenex Inc, Key Competitors 55

Athenex Inc, Key Employees 56

Athenex Inc, Subsidiaries 58

Athenex Inc, Joint Venture 59

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Athenex Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company's orascovery products candidates include oral formulations of paclitaxel (Oraxol), irinotecan (Oratecan), and docetaxel (Oradoxel) for the treatment of metastatic breast, colorectal, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancers. Its Src kinase product candidates comprises KX-01, a novel orally administered small molecule compound for the treatment of actinic keratosis; and KX-02 for solid tumors. Athenex offers services including drug discovery, drug formulation and clinical development, API manufacturing services. The company partners with pharmaceutical companies, universities and research institutions for the advancement and commercialization of its products. It has operations with product manufacturing facilities in the US, China, Taiwan and Hong Kong. Athenex is headquartered in Buffalo, New York, the US.

Athenex Inc (ATNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11

Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Athenex Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 14

Venture Financing 15

Athenex Raises USD20 Million in Venture Debt Financing 15

Athenex Raises USD38 Million in Financing 16

Kinex Pharma Raises USD10 Million in Venture Financing 17

Kinex Pharma Raises USD74.4 Million in Venture Financing 18

Kinex Pharma Raises USD 0.3 Million In Venture Financing 19

Kinex Pharma Raises Funds In First Tranche Of Financing Round 20

Kinex Pharma Raises USD 5 Million In Venture Financing 21

Private Equity 22

Athenex to Raise USD50 Million in Equity Financing 22

Partnerships 23

Athenex to Form Joint Venture with Xiangxue Life Sciences 23

Athenex Forms Joint Venture with SunGen Pharma 24

Athenex Enters into Agreement with Imuna Pharm 25

Athenex Enters into Partnership with Eli Lilly and Company 26

Athenex Enters into Agreement with Fort Schuyler Management 27

Licensing Agreements 28

Athenex Enters into Licensing Agreement with Avalon PolyTom 28

Almirall to Enter into Licensing Agreement with Athenex for KX2-391 30

Athenex to Enter into Licensing Agreement with Gland Pharma 31

Athenex to Enter into Licensing Agreement with Gland Pharma 32

Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 33

PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 34

Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 35

Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 37

Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 39

Equity Offering 41

Athenex Completes Partial Exercise of Over-Allotment Option of Public Offering of Shares for USD72.7 Million 41

Athenex Raises USD76 Million in IPO 43

Athenex Raises USD3.5 Million in Private Placement of Shares 45

Athenex Raises USD5 Million in Private Placement of Shares 46

Athenex Raises USD6.6 Million in Private Placement of Shares 47

Kinex Pharma Raises Funds through Private Placement of Shares 48

Athenex Raises USD4 Million in Private Placement of Shares 49

Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 50

Kinex Pharma Completes Private Placement Of Shares For USD 40 Million 51

Acquisition 52

Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 52

Athenex Acquires Polymed Therapeutics 53

Kinex Pharma Acquires QuaDPharma for USD5.5 Million 54

Athenex Inc-Key Competitors 55

Athenex Inc-Key Employees 56

Athenex Inc-Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Joint Venture 59

Recent Developments 60

Financial Announcements 60

Aug 14, 2018: Athenex reports second quarter 2018 financial results 60

May 14, 2018: Athenex Announces First Quarter 2018 Results 63

Mar 26, 2018: Athenex Announces Fourth Quarter and Full-Year 2017 Results 65

Nov 09, 2017: Athenex Announces Third Quarter 2017 Results 67

Aug 14, 2017: Athenex Announces Second Quarter 2017 Results 70

Corporate Communications 73

Aug 20, 2018: Athenex names Randoll Sze as Chief Financial Officer 73

Jul 09, 2018: Athenex Appoints Timothy Cook As Senior Vice President Of Global Commercial Oncology 74

Jun 15, 2018: Athenex Appoints Benson Tsang As Board Director 75

Apr 30, 2018: Athenex Announces Transition of James Zukin from Board of Directors to Advisory Role 76

Dec 01, 2017: Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle 77

Mar 01, 2017: Athenex announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer 78

Feb 27, 2017: Athenex appoints veteran J. Nick Riehle as Chief Financial Officer 79

Government and Public Interest 80

Sep 11, 2017: Athenex Announces Grant Disbursement Agreement with New York State for Dunkirk Facility 80

Product News 81

Oct 15, 2018: Athenex and Xiangxue Life Sciences announce preliminary results of patients receiving T-Cell receptor affinity enhancing specific T-Cell therapy (TAEST) showed encouraging positive clinical signals 81

Aug 10, 2017: Athenex Pharma Solutions, an Athenex, Company, Launches Three New Sterile Injectable Products from its 503(B) Facility 82

Aug 01, 2017: Athenex Announces Recent Product Launches in Commercial Business 83

Clinical Trials 84

Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting 84

Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis 85

Other Significant Developments 86

Jul 18, 2018: PolyU-axis therapeutics joint center for immunotherapy launched to develop innovative cancer treatments 86

Jul 02, 2018: Athenex forms new alliances in Asia to expand oncology pipeline 87

Feb 13, 2018: Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units 88

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Athenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Athenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Athenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Athenex Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11

Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 14

Athenex Raises USD20 Million in Venture Debt Financing 15

Athenex Raises USD38 Million in Financing 16

Kinex Pharma Raises USD10 Million in Venture Financing 17

Kinex Pharma Raises USD74.4 Million in Venture Financing 18

Kinex Pharma Raises USD 0.3 Million In Venture Financing 19

Kinex Pharma Raises Funds In First Tranche Of Financing Round 20

Kinex Pharma Raises USD 5 Million In Venture Financing 21

Athenex to Raise USD50 Million in Equity Financing 22

Athenex to Form Joint Venture with Xiangxue Life Sciences 23

Athenex Forms Joint Venture with SunGen Pharma 24

Athenex Enters into Agreement with Imuna Pharm 25

Athenex Enters into Partnership with Eli Lilly and Company 26

Athenex Enters into Agreement with Fort Schuyler Management 27

Athenex Enters into Licensing Agreement with Avalon PolyTom 28

Almirall to Enter into Licensing Agreement with Athenex for KX2-391 30

Athenex to Enter into Licensing Agreement with Gland Pharma 31

Athenex to Enter into Licensing Agreement with Gland Pharma 32

Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 33

PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 34

Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 35

Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 37

Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 39

Athenex Completes Partial Exercise of Over-Allotment Option of Public Offering of Shares for USD72.7 Million 41

Athenex Raises USD76 Million in IPO 43

Athenex Raises USD3.5 Million in Private Placement of Shares 45

Athenex Raises USD5 Million in Private Placement of Shares 46

Athenex Raises USD6.6 Million in Private Placement of Shares 47

Kinex Pharma Raises Funds through Private Placement of Shares 48

Athenex Raises USD4 Million in Private Placement of Shares 49

Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 50

Kinex Pharma Completes Private Placement Of Shares For USD 40 Million 51

Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 52

Athenex Acquires Polymed Therapeutics 53

Kinex Pharma Acquires QuaDPharma for USD5.5 Million 54

Athenex Inc, Key Competitors 55

Athenex Inc, Key Employees 56

Athenex Inc, Subsidiaries 58

Athenex Inc, Joint Venture 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Athenex Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.